American Journal of Clinical Nutrition, Vol 62, 1181-1187, Copyright © 1995 by The American Society for Clinical Nutrition, Inc

ORIGINAL RESEARCH COMMUNICATIONS

Efficacies of dexfenfluramine and fluoxetine in preventing weight gain after smoking cessation

B Spring, J Wurtman, R Wurtman, A el-Khoury, H Goldberg, J McDermott and R Pingitore
Department of Psychology, University of Health Sciences, Chicago Medical School, IL 60064, USA.

We tested whether 14 wk of dexfenfluramine (30 mg) or fluoxetine (40 mg) treatment would prevent weight gain after subjects quit smoking. Normal-weight women (n = 144) were randomly assigned to drug or placebo on a double-blind basis for 2 wk before quitting smoking and 12 wk thereafter. The fluoxetine group had more dropouts (28/49, 57.1%) than the dexfenfluramine group (17/47, 36.2%), with an intermediate number of dropouts from the placebo group (21/48, 43.8%). All groups gained weight during treatment, but their amount and pattern of weight gain differed. In the first month after quitting smoking, the placebo group gained more weight than either the dexfenfluramine or fluoxetine group (P < 0.05). By 2 mo postcessation, dexfenfluramine still suppressed weight gain in comparison with placebo (P < 0.05); weight gain with fluoxetine was not differentiable from either dexfenfluramine or placebo. By 3 mo postcessation, the dexfenfluramine group had gained 1.0 +/- 0.7 kg, significantly less than either the placebo (3.5 +/- 0.7 kg) or fluoxetine (2.7 +/- 0.5 kg) groups. Three months after drug discontinuation, formerly medicated, but not placebo patients, showed additional weight gain, eliminating differences between groups. Results indicate that weight gain, an adverse accompaniment of smoking cessation, can be minimized to some degree by serotoninergic drugs, although only for the duration of drug treatment.

This article has been cited by other articles:

				T. V. Cooper, B. S. Hanson, R. S. Burke, and Y. M. Hunt Sequential Treatment for Nicotine Dependence and Postcessation Weight Concern in a Female Diagnosed with Paranoid Schizophrenia Clinical Case Studies, August 1, 2008; 7(4): 340 - 355. [Abstract] [PDF]

				W. H. Berrettini and C. E. Lerman Pharmacotherapy and Pharmacogenetics of Nicotine Dependence Am J Psychiatry, August 1, 2005; 162(8): 1441 - 1451. [Abstract] [Full Text] [PDF]

				C. Lerman, F. Patterson, and W. Berrettini Treating Tobacco Dependence: State of the Science and New Directions J. Clin. Oncol., January 10, 2005; 23(2): 311 - 323. [Abstract] [Full Text] [PDF]

				G. A. Bray and F. L. Greenway Current and Potential Drugs for Treatment of Obesity Endocr. Rev., December 1, 1999; 20(6): 805 - 875. [Abstract] [Full Text]

				T. Danielsson, S. Rössner, A. Westin, and K. Jones Open randomised trial of intermittent very low energy diet together with nicotine gum for stopping smoking in women who gained weight in previous attempts to quit • Commentary: results are unlikely to be as good in routine practice BMJ, August 21, 1999; 319(7208): 490 - 494. [Abstract] [Full Text]